#Drug1 may increase the photosensitizing activities of #Drug2.
#Drug1 may increase the anticholinergic activities of #Drug2.
The bioavailability of #Drug2 can be decreased when combined with #Drug1.
The metabolism of #Drug2 can be increased when combined with #Drug1.
#Drug1 may decrease the vasoconstricting activities of #Drug2.
#Drug1 may increase the anticoagulant activities of #Drug2.
#Drug1 may increase the ototoxic activities of #Drug2.
The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.
#Drug1 may increase the hypoglycemic activities of #Drug2.
#Drug1 may increase the antihypertensive activities of #Drug2.
The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.
#Drug1 may decrease the anticoagulant activities of #Drug2.
The absorption of #Drug2 can be decreased when combined with #Drug1.
#Drug1 may decrease the bronchodilatory activities of #Drug2.
#Drug1 may increase the cardiotoxic activities of #Drug2.
#Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2.
#Drug1 may decrease the neuromuscular blocking activities of #Drug2.
#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.
#Drug1 may increase the vasoconstricting activities of #Drug2.
#Drug1 may increase the QTc-prolonging activities of #Drug2.
#Drug1 may increase the neuromuscular blocking activities of #Drug2.
#Drug1 may increase the adverse neuromuscular activities of #Drug2.
#Drug1 may increase the stimulatory activities of #Drug2.
#Drug1 may increase the hypocalcemic activities of #Drug2.
#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.
#Drug1 may decrease the antiplatelet activities of #Drug2.
#Drug1 may increase the neuroexcitatory activities of #Drug2.
#Drug1 may increase the dermatologic adverse activities of #Drug2.
#Drug1 may decrease the diuretic activities of #Drug2.
#Drug1 may increase the orthostatic hypotensive activities of #Drug2.
The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.
#Drug1 may increase the sedative activities of #Drug2.
The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2.
#Drug1 may increase the immunosuppressive activities of #Drug2.
#Drug1 may increase the neurotoxic activities of #Drug2.
#Drug1 may increase the antipsychotic activities of #Drug2.
#Drug1 may decrease the antihypertensive activities of #Drug2.
#Drug1 may increase the vasodilatory activities of #Drug2.
#Drug1 may increase the constipating activities of #Drug2.
#Drug1 may increase the respiratory depressant activities of #Drug2.
#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.
The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.
The protein binding of #Drug2 can be decreased when combined with #Drug1.
#Drug1 may increase the central neurotoxic activities of #Drug2.
#Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent.
#Drug1 may increase the bronchoconstrictory activities of #Drug2.
The metabolism of #Drug2 can be decreased when combined with #Drug1.
#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.
The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.
The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1.
#Drug1 may increase the hypercalcemic activities of #Drug2.
#Drug1 may decrease the analgesic activities of #Drug2.
#Drug1 may increase the antiplatelet activities of #Drug2.
#Drug1 may increase the bradycardic activities of #Drug2.
#Drug1 may increase the hyponatremic activities of #Drug2.
The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.
#Drug1 may increase the nephrotoxic activities of #Drug2.
#Drug1 may decrease the cardiotoxic activities of #Drug2.
#Drug1 may increase the ulcerogenic activities of #Drug2.
#Drug1 may increase the hypotensive activities of #Drug2.
#Drug1 may decrease the stimulatory activities of #Drug2.
The bioavailability of #Drug2 can be increased when combined with #Drug1.
#Drug1 may increase the myelosuppressive activities of #Drug2.
#Drug1 may increase the serotonergic activities of #Drug2.
#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.
The risk or severity of bleeding can be increased when #Drug1 is combined with #Drug2.
#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.
#Drug1 may increase the hyperkalemic activities of #Drug2.
#Drug1 may increase the analgesic activities of #Drug2.
The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.
#Drug1 may increase the hypertensive activities of #Drug2.
#Drug1 may decrease the excretion rate of #Drug2 which could result in a higher serum level.
The serum concentration of #Drug2 can be increased when it is combined with #Drug1.
#Drug1 may increase the fluid retaining activities of #Drug2.
The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.
#Drug1 may decrease the sedative activities of #Drug2.
The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.
#Drug1 may increase the hyperglycemic activities of #Drug2.
#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.
#Drug1 may increase the hepatotoxic activities of #Drug2.
#Drug1 may increase the thrombogenic activities of #Drug2.
#Drug1 may increase the arrhythmogenic activities of #Drug2.
#Drug1 may increase the hypokalemic activities of #Drug2.
#Drug1 may increase the vasopressor activities of #Drug2.
#Drug1 may increase the tachycardic activities of #Drug2.
The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.
